 | |
Subscribe to our Email List
| |
| | | Professor Clive Page, PhD
Chairman of the Board
Professor Page, chairman of Verona Pharma since September 2006, is a Professor of Pharmacology and Director of the Sackler Institute of Pulmonary Pharmacology in the Division of Pharmaceutical Sciences, King's College, University of London. He is a recognised authority in the area of lung diseases and inflammation, as well as being internationally recognised for his work in connection with heparin and related molecules as anti-inflammatory drugs. He is highly regarded internationally as a consultant to both the pharmaceutical and biotech industries and he is currently a consultant to Johnson & Johnson and Z-cube, the venture capital arm of Zambon Group S.p.A. His academic research has resulted in more than 200 scientific publications and he has edited a number of leading books in pharmacology of lung diseases. Professor Page is one of the inventors of the NAIPS technology being developed by Verona Pharma.
|
| | | Professor Michael Walker, PhD
Chief Executive Officer
Professor Walker has been a director and CEO of Verona Pharma since September 2006. He is an Emeritus Professor at the Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Canada and has founded and managed various biotech companies in Canada and the UK. His research interests are wide including many aspects of general pharmacology (from basic to clinical studies), marine toxins and respiratory and cardiac pharmacology. Professor Walker was the founder of Rhythm Search Developments (RSD) Ltd., which company evolved into Nortran Pharmaceuticals Inc. and subsequently Cardiome Pharma Corp. (TSX:COM, NASDAQ: CRME) whose drug, RSD1235, for the acute termination of atrial fibrillation (a disorder of heart beating), is currently the subject of a New Drug Application filed with the US Food and Drug Administration.
|
| | | Claire Poll, LLB
Corporate Director
Ms Poll, a director of Verona Pharma since September 2006, has significant experience as a legal and corporate executive for start-up and mature companies internationally. She was a former director of corporate development for Inmarsat Ventures plc in London, an international provider of satellite communication services, where she had responsibility for group strategy, mergers and acquisitions and managed the divestment of Inmarsat to a group of venture capitalists for approximately £900 million.
|
| | | Professor Trevor Jones, CBE PhD DSc FKC FPS CChem FRSC MCPP FFPM
Non-Executive Director
Professor Jones has been a director of Verona Pharma since September 2006. For 10 years until 2004, he was Director General of the Association of the British Pharmaceutical Industry (ABPI), the body representing the interests of some 100 national and international pharmaceutical companies. From 1987 to 1994, he was a director of The Wellcome Foundation, where he was responsible for R&D including the development of a number of significant new products, including Zovirax (anti-herpes), Retrovir (anti-HIV), Malarone (Malaria) and Lamictal (anti-epileptic). In 2003, Professor Jones received a CBE for services to the pharmaceutical industry and, in 2005, was the winner of the SCRIP Life Time Achievement award for his contribution to the pharmaceutical sciences and industry. He is Deputy Chairman of Council and a visiting professor at King's College, London, and is a member of the Boards of Allergan Inc (USA) and NextPharma Technologies Limited and Chairman of AIM-quoted ReNeuron Group plc and the Dutch biotech company BAC BV.
|
| | | Stuart Bottomley
Non-Executive Director
Mr Bottomley has been a director of Verona Pharma since February 2005. He worked initially as a stockbroker for 9 years, before joining Dawnay Day where he worked as a portfolio manager for the Target Group of Unit Trusts. During his time with Target, he successfully managed the Special Situations Fund and Target Energy. In 1984, he joined Fidelity International in London, working with the ERISA group, focused on UK and European markets. Since leaving Fidelity, Mr Bottomley has consulted for numerous private and public companies on IPOs and other fundraisings.
|
| | | Patrick Humphrey, PhD, DSc, OBE
Non-Executive Director
Dr Humphrey graduated from the School of Pharmacy, University of London, in 1968, with a strong interest in drug receptor theory. After obtaining a PhD in pharmacology at St Mary's Hospital Medical School, he joined Allen and Hanburys, at Ware, U.K., to initiate a project on migraine. His work on cerebrovascular pharmacology led directly to the development of sumatriptan, the prototype of a new drug class for the treatment of migraine. During this time, he became the leading laboratory scientist in Glaxo and the Director of the Glaxo Division of Pharmacology that was not only instrumental in the discovery of sumatriptan, but also naratriptan, alosetron, ondansetron, vapiprost and salmeterol. Dr Humphrey has received several important academic honours, including an honorary professorship from the University of Cambridge, as well as the Royal Society's Mullard medal. In 1999, he was awarded the OBE (Officer of the Order of the British Empire) by the Queen of England for "services to migraine research". He maintains a passion for research aimed at drug discovery and was latterly Head of Research at Theravance in South San Francisco from 2001 to January 2008, during which time several exciting potential drugs emerged including the anti-MRSA antibiotic, telavancin. He has some 300 published scientific papers and book chapters to his name and was ranked 4th in the list of total literature citations in Pharmacology and Toxicology from 1994-2004.
|
| | |
